One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Primary and secondary non-response: in need of operational definitions in observational studies
Enriqueta Vallejo-Yagüe, Edward C Keystone, Sreemanjari Kandhasamy, Raphael Micheroli, Axel Finckh, Andrea Michelle Burden
doi : 10.1136/annrheumdis-2021-220202
Annals of the Rheumatic Diseases 2021;80:961-964
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial
Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren
doi : 10.1136/annrheumdis-2020-219825
Annals of the Rheumatic Diseases 2021;80:965-973
To compare outcomes of different treatment schedules from the care in early rheumatoid arthritis (CareRA) trial over 5 years.
Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study
Xanthe Marijn Edmée Matthijssen, Fenne Wouters, Navkiran Sidhu, Ellis Niemantsverdriet, Annette van der Helm-van Mil
doi : 10.1136/annrheumdis-2020-219302
Annals of the Rheumatic Diseases 2021;80:974-980
Clinically evident tenosynovitis can be seen in established rheumatoid arthritis (RA). Imaging research has recently shown that tenosynovitis at small joints occurs in early RA, contributes to typical RA symptoms (including joint swelling) and is infrequent in healthy controls. Imaging-detectable tenosynovitis is often not recognisable at joint examination, hence its prevalence can therefore be underestimated. We hypothesised that if MRI-detectable tenosynovitis is a true RA feature, the sensitivity for RA is high, in both anti-citrullinated protein antibodies (ACPA)-positive and ACPA-negative RA, and lower in other diseases that are associated with enthesitis (such as spondyloarthritis (SpA) and psoriatic arthritis (PsA)). So far, no large MRI study addressed these questions.
Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial
Ho So, Isaac T Cheng, Sze-Lok Lau, Evelyn Chow, Tommy Lam, Vivian W Hung, Edmund K Li, James F Griffith, Vivian W Lee, Lin Shi, Junbin Huang, Kitty Yan Kwok, Cheuk-Wan Yim, Tena K Li, Vincent Lo, Jolie Lee, Jack Jock-Wai Lee, Ling Qin, Lai-Shan Tam
doi : 10.1136/annrheumdis-2021-219846
Annals of the Rheumatic Diseases 2021;80:981-988
To evaluate the effects of denosumab on erosion healing at 2–4 metacarpophalangeal (MCP) head as determined by high-resolution peripheral quantitative CT (HR-pQCT) in patients with rheumatoid arthritis (RA) with stable disease.
Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of Defense Biorepository
Karen H Costenbader, Michael DiIorio, Su H Chu, Jing Cui, Jeffrey A Sparks, Bing Lu, LauraKay Moss, Lindsay Kelmenson, Marie Feser, Jess Edison, Clary Clish, Jessica Lasky-Su, Kevin D Deane, Elizabeth W Karlson
doi : 10.1136/annrheumdis-2020-219682
Annals of the Rheumatic Diseases 2021;80:989-996
We sought to identify metabolic changes potentially related to rheumatoid arthritis (RA) pathogenesis occurring in the blood prior to its diagnosis.
Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020
Wenhui Xie, Hong Huang, Guangtao Li, Yanjie Hao, Yanni Gui, Yu Wang, Xuerong Deng, Juan Zhao, Yan Geng, LanLan Ji, Xiaohui Zhang, Zhibo Song, Zhuoli Zhang
doi : 10.1136/annrheumdis-2021-220112
Annals of the Rheumatic Diseases 2021;80:997-1003
To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering and discontinuation in patients with rheumatoid arthritis (RA) commencing GC with concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Atul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, Xenofon Baraliakos, Lianne S Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S Kanik, Désirée van der Heijde
doi : 10.1136/annrheumdis-2020-219601
Annals of the Rheumatic Diseases 2021;80:1004-1013
To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS).
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
James Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi
doi : 10.1136/annrheumdis-2020-219406
Annals of the Rheumatic Diseases 2021;80:1014-1021
To investigate the efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA).
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
Robert BM Landewé, Lianne S Gensler, Denis Poddubnyy, Proton Rahman, Maja Hojnik, Xiaoqi Li, Soyi Liu Leage, David Adams, Hilde Carlier, Filip Van den Bosch
doi : 10.1136/annrheumdis-2020-219717
Annals of the Rheumatic Diseases 2021;80:1022-1030
The objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission.
Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren’s syndrome-like phenotype in mice
Hiroyuki Nakamura, Tsutomu Tanaka, Thomas Pranzatelli, Youngmi Ji, Hongen Yin, Paola Perez, Sandra A Afione, Shyh-Ing Jang, Corrine Goldsmith, Chang Yu Zheng, William D Swaim, Blake M Warner, Noriyuki Hirata, Masayuki Noguchi, Tatsuya Atsumi, John A Chiorini
doi : 10.1136/annrheumdis-2020-219649
Annals of the Rheumatic Diseases 2021;80:1031-1039
Sjögren’s syndrome (SS) is an autoimmune sialadenitis with unknown aetiology. Although extensive research implicated an abnormal immune response associated with lymphocytes, an initiating event mediated by salivary gland epithelial cell (SGEC) abnormalities causing activation is poorly characterised. Transcriptome studies have suggested alternations in lysosomal function are associated with SS, but a cause and effect linkage has not been established. In this study, we demonstrated that altered lysosome activity in SGECs by expression of lysosome-associated membrane protein 3 (LAMP3) can initiate an autoimmune response with autoantibody production and salivary dysfunction similar to SS.
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
Marialbert Acosta-Herrera, Martin Kerick, Elena Lopéz-Isac, Shervin Assassi, Lorenzo Beretta, Carmen Pilar Simeón-Aznar, Norberto Ortego-Centeno, International SSc Group, Susanna M Proudman, Australian Scleroderma Interest Group (ASIG), Nicolas Hunzelmann, Gianluca Moroncini, Jeska K de Vries-Bouwstra, Gisela Orozco, Anne Barton, Ariane L Herrick, Chikashi Terao, Yannick Allanore, Matthew A Brown, Timothy RDJ Radstake, Carmen Fonseca, Christopher P Denton, Maureen D Mayes, Javier Martin
doi : 10.1136/annrheumdis-2021-219884
Annals of the Rheumatic Diseases 2021;80:1040-1047
The greatest genetic effect reported for systemic sclerosis (SSc) lies in the major histocompatibility complex (MHC) locus. Leveraging the largest SSc genome-wide association study, we aimed to fine-map this region to identify novel human leucocyte antigen (HLA) genetic variants associated with SSc susceptibility and its main clinical and serological subtypes.
X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc)
Christina Bergmann, Ludwig Hallenberger, Sara Chenguiti Fakhouri, Benita Merlevede, Amelie Brandt, Clara Dees, Honglin Zhu, Ariella Zehender, Xiang Zhou, Annemarie Schwab, Chih-Wei Chen, Andrea Hermina Györfi, Alexandru Emil Matei, Debomita Chakraborty, Thuong Trinh-Minh, Simon Rauber, Roland Coras, Aline Bozec, Alexander Kreuter, Mirjana Ziemer, Georg Schett, Jörg H W Distler
doi : 10.1136/annrheumdis-2020-219822
Annals of the Rheumatic Diseases 2021;80:1048-1056
X-linked inhibitor of apoptosis protein (XIAP) is a multifunctional protein with important functions in apoptosis, cellular differentiation and cytoskeletal organisation and is emerging as potential target for the treatment of various cancers. The aim of the current study was to investigate the role of XIAP in the pathogenesis of systemic sclerosis (SSc).
Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis
Naomi Tsuchida, Yosuke Kunishita, Yuri Uchiyama, Yohei Kirino, Makiko Enaka, Yukie Yamaguchi, Masataka Taguri, Shoji Yamanaka, Kaoru Takase-Minegishi, Ryusuke Yoshimi, Satoshi Fujii, Hideaki Nakajima, Naomichi Matsumoto
doi : 10.1136/annrheumdis-2021-220089
Annals of the Rheumatic Diseases 2021;80:1057-1061
To determine clinical and genetic features of individuals with relapsing polychondritis (RP) likely caused by pathogenic somatic variants in ubiquitin-like modifier activating enzyme 1 (UBA1).
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
Felix Eckstein, Marc C Hochberg, Hans Guehring, Flavie Moreau, Victor Ona, Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Benjamin Daelken, Oliver Guenther, Christoph Ladel, Martin Michaelis, Philip G Conaghan
doi : 10.1136/annrheumdis-2020-219181
Annals of the Rheumatic Diseases 2021;80:1062-1069
The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results.
Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis
Julia Steinberg, Lorraine Southam, Andreas Fontalis, Matthew J Clark, Raveen L Jayasuriya, Diane Swift, Karan M Shah, Roger A Brooks, Andrew W McCaskie, Jeremy Mark Wilkinson, Eleftheria Zeggini
doi : 10.1136/annrheumdis-2020-219760
Annals of the Rheumatic Diseases 2021;80:1070-1074
To determine how gene expression profiles in osteoarthritis joint tissues relate to patient phenotypes and whether molecular subtypes can be reproducibly captured by a molecular classification algorithm.
Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease
Emma Garcia-Melchor, Giacomo Cafaro, Lucy MacDonald, Lindsay A N Crowe, Shatakshi Sood, Michael McLean, Umberto G Fazzi, Iain B McInnes, Moeed Akbar, Neal L Millar
doi : 10.1136/annrheumdis-2020-219335
Annals of the Rheumatic Diseases 2021;80:1075-1085
Increasing evidence suggests that inflammatory mechanisms play a key role in chronic tendon disease. After observing T cell signatures in human tendinopathy, we explored the interaction between T cells and tendon stromal cells or tenocytes to define their functional contribution to tissue remodelling and inflammation amplification and hence disease perpetuation.
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling
doi : 10.1136/annrheumdis-2021-219845
Annals of the Rheumatic Diseases 2021;80:1086-1093
To estimate absolute and relative risks for all-cause mortality and for severe COVID-19 in inflammatory joint diseases (IJDs) and with antirheumatic therapies.
Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016–2020
Huixin Wang, Sarah Stewart, Ben Darlow, Ben Horgan, Graham Hosie, Jane Clark, Nicola Dalbeth
doi : 10.1136/annrheumdis-2021-220138
Annals of the Rheumatic Diseases 2021;80:1095-1096
Onset of rheumatoid arthritis after COVID-19: coincidence or connected?
Veerle F A M Derksen, Theresa Kissel, Femke B G Lamers-Karnebeek, Arie E van der Bijl, Annemarie C Venhuizen, Tom W J Huizinga, René E M Toes, Anna H E Roukens, Diane van der Woude
doi : 10.1136/annrheumdis-2021-219859
Annals of the Rheumatic Diseases 2021;80:1096-1098
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
Brian J Boyarsky, Jake A Ruddy, Caoilfhionn M Connolly, Michael T Ou, William A Werbel, Jacqueline M Garonzik-Wang, Dorry L Segev, Julie J Paik
doi : 10.1136/annrheumdis-2021-220289
Annals of the Rheumatic Diseases 2021;80:1098-1099
Safety of?the?first?dose of?mRNA SARS-CoV-2?vaccines in?patients with rheumatic and musculoskeletal diseases
Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Robin K Avery, William A Werbel, Dorry L Segev, Jacqueline Garonzik-Wang, Julie J Paik
doi : 10.1136/annrheumdis-2021-220231
Annals of the Rheumatic Diseases 2021;80:1100-1101
SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study
Arthur Mageau, Geoffrey Aldebert, Damien Van Gysel, Thomas Papo, Jean-François Timsit, Karim Sacre
doi : 10.1136/annrheumdis-2021-220010
Annals of the Rheumatic Diseases 2021;80:1101-1102
Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab
Marcia A Friedman, Kevin L Winthrop
doi : 10.1136/annrheumdis-2021-220088
Annals of the Rheumatic Diseases 2021;80:1102-1104
New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS
Florence Assan, Raphaele Seror, Xavier Mariette, Gaetane Nocturne
doi : 10.1136/annrheumdis-2019-216222
Annals of the Rheumatic Diseases 2021;80:e122
Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS’ by Assan et al
Martin Aringer, Karen Costenbader, Thomas Dörner, Sindhu R Johnson
doi : 10.1136/annrheumdis-2019-216250
Annals of the Rheumatic Diseases 2021;80:e123
Role of ANA testing in the classification of patients with systemic lupus erythematosus
David S Pisetsky1,2, Diane M Spencer1,2, Brad Rovin3, Peter E Lipsky
doi : 10.1136/annrheumdis-2019-216259
Annals of the Rheumatic Diseases 2021;80:e124
Response to: ‘Role of ANA testing in the classification of patients with systemic lupus erythematosus’ by Pisetsky et al
Martin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson
doi : 10.1136/annrheumdis-2019-216337
Annals of the Rheumatic Diseases 2021;80:e125
Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?
Huihui Chi, Jialin Teng, Zhihong Wang, Chengde Yang, Yutong Su
doi : 10.1136/annrheumdis-2019-216253
Annals of the Rheumatic Diseases 2021;80:e126
Response to: ‘Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?’ by Chi et al
Martin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson
doi : 10.1136/annrheumdis-2019-216338
Annals of the Rheumatic Diseases 2021;80:e127
Titre-specific positive predictive value of antinuclear antibody patterns
Jean-Baptiste Vulsteke, Lieve Van Hoovels, Philippe Willems, Bert Vander Cruyssen, Steven Vanderschueren, Rene Westhovens, Daniel Blockmans, Ellen De Langhe, Xavier Bossuyt
doi : 10.1136/annrheumdis-2019-216245
Annals of the Rheumatic Diseases 2021;80:e128
Response to ‘Titre-specific positive predictive value of anti-nuclear antibody patterns’ by Vulsteke et al
Jan Damoiseaux, Luís Eduardo Coelho Andrade, Marvin J Fritzler, Manfred Herold, Maria Infantino, Carlos von Muhlen
doi : 10.1136/annrheumdis-2019-216266
Annals of the Rheumatic Diseases 2021;80:e129
Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2
Sheng-Xiao Zhang, Jia Wang, He-Hua Sun, Jia-Qian Zhang, Guang-Ying Liu, Jing Luo, Pei-Feng He, Xiao-Feng Li
doi : 10.1136/annrheumdis-2019-216246
Annals of the Rheumatic Diseases 2021;80:e130
Response to: ‘Circulating regulatory T cells were absolutelydecreased in dermatomyositis/polymyositispatients and restored by low-dose IL-2’ by Zhang et al
David Klatzmann
doi : 10.1136/annrheumdis-2019-216267
Annals of the Rheumatic Diseases 2021;80:e131
Standardisation of myositis-specific antibodies: where are we today?
Michael Mahler, Jean-Baptiste Vulsteke, Xavier Bossuyt, Ellen De Langhe, Minoru Satoh
doi : 10.1136/annrheumdis-2019-216003
Annals of the Rheumatic Diseases 2021;80:e132
What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica?
Jean Jacques Dubost, Bruno Pereira, Angelique Fan, Martin Soubrier
doi : 10.1136/annrheumdis-2019-216050
Annals of the Rheumatic Diseases 2021;80:e133
Diabetes mellitus in ankylosing spondylitis
Kuan-Fu Liao, Yu-Hung Kuo, Shih-Wei Lai
doi : 10.1136/annrheumdis-2019-216221
Annals of the Rheumatic Diseases 2021;80:e134
Response to: ‘Diabetes mellitus in ankylosing spondylitis’ by Liao et al
Sylvain Mathieu, Martin Soubrier
doi : 10.1136/annrheumdis-2019-216249
Annals of the Rheumatic Diseases 2021;80:e135
Association between ankylosing spondylitis and venous thromboembolism
Shih-Wei Lai
doi : 10.1136/annrheumdis-2019-215854
Annals of the Rheumatic Diseases 2021;80:e136
Risk of gout flares after vaccination
Shih-Wei Lai, Yu-Hung Kuo, Kuan-Fu Liao
doi : 10.1136/annrheumdis-2019-216146
Annals of the Rheumatic Diseases 2021;80:e137
‘DESIRABLE’ or not?
Nupoor Acharya, Arghya Chattopadhyay, Varun Dhir
doi : 10.1136/annrheumdis-2019-216236
Annals of the Rheumatic Diseases 2021;80:e138
Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis
doi : 10.1136/annrheumdis-2017-211351ret
Annals of the Rheumatic Diseases 2021;80:e139
